|Bid||4.50 x 100|
|Ask||4.70 x 100|
|Day's Range||4.60 - 4.85|
|52 Week Range||3.80 - 8.19|
|PE Ratio (TTM)||-3.09|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||19.20|
LEXINGTON, Mass., July 18, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that the last patient has completed dosing in Aldeyra's single-center, double-blind, randomized Phase 2a clinical trial of ADX-102 in Dry Eye Disease (DED). ADX-102 and other product candidates generated from Aldeyra's aldehyde trap platform sequester and facilitate the degradation of aldehydes, a class of endogenously generated pro-inflammatory mediators that are elevated in DED patients.
The poster presentation will highlight the differentiated effects of ADX-102 on inflammatory cell migration and activation, lung function, and biochemical mediators of inflammation in a mouse model of endotoxin-induced lung injury. ADX-102, a novel aldehyde sequestering agent, has been shown in animal models to reduce pro-inflammatory cytokines, decrease tissue edema in allergic and contact dermatitis, reduce healing time and fibrosis in radiation-induced mucositis, and diminish inflammatory pain. In Phase 2 clinical trials in patients with noninfectious anterior uveitis and allergic conjunctivitis, two ocular inflammatory diseases, ADX-102 was statistically superior to control in reducing inflammation.
Aldeyra Therapeutics saw its shares slide on Wednesday after the company said its allergic conjunctivitis drug missed the primary endpoint in this Phase 2b trial.